Bispecific Antibody Production via CH3 Domain Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biological therapeutics, such as monoclonal antibodies, are limited by their monospecific nature, which fails to effectively address multifactorial diseases as they can only interfere with a single step in complex disease processes, and bispecific antibodies face challenges in controlling the composition and reproducibility of mixed antibody preparations.
Innovation Solution
The development of methods to produce bispecific antibodies with improved proportions using techniques like knob-into-hole technology and electrostatic engineering of the CH3 domains, allowing for preferential pairing of Ig-like molecules to achieve high percentages of desired bispecific antibodies in a single cell culture, thereby simplifying drug development and manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If monoclonal antibodies are used to treat diseases, then they can bind to a single specific epitope and provide consistent therapeutic effect, but they fail to address multifactorial diseases that involve multiple disease mediators and pathways
Solution Approach 1:
The patent applies multi-functionality by creating polyclonal antibody preparations that can simultaneously target multiple epitopes and disease mediators. The engineered B-cell lines produce heterogeneous antibody populations with different specificities, enabling a single therapeutic preparation to address multiple aspects of complex diseases involving redundant or synergistic action of different disease mediators.
2Adaptability or versatility
If polyclonal antibodies are produced from pooled human serum, then they can target multiple epitopes and disease mediators, but the products show considerable variation between batches and depend on donor blood availability
Solution Approach 1:
The patent applies self-service by using immortalized B-cell lines that autonomously produce polyclonal antibody preparations with consistent composition. The engineered cell lines serve as self-sufficient factories, eliminating dependence on donor blood availability and ensuring reproducible batch-to-batch quality through controlled in vitro production rather than reliance on human serum pools.
Solution Approach 2:
The patent applies preliminary action by pre-engineering B-cell lines with specific repertoires of antibody genes before production. The cell lines are designed in advance to express defined sets of heavy and light chain variants, ensuring that the resulting polyclonal preparations have controlled and reproducible compositions targeting specific epitopes, rather than relying on unpredictable natural immune responses from different donors.
3Adaptability or versatility
If mixtures of monoclonal antibodies are produced separately and combined, then they can target multiple epitopes, but the complexity of producing and regulating multiple separate antibodies increases
Solution Approach 1:
The patent applies merging by combining multiple monoclonal antibody production capabilities into a single polyclonal preparation from one cell line. Instead of producing separate monoclonal antibodies and combining them, the engineered B-cell lines simultaneously express multiple heavy and light chain variants that assemble into heterogeneous antibody molecules, achieving multi-epitope targeting through a unified production and regulatory pathway.
Data Source
AI summary
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.